Ritholtz Wealth Management Increases Stake in Johnson & Johnson $JNJ

Ritholtz Wealth Management grew its position in Johnson & Johnson (NYSE:JNJ) by 15.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,380 shares of the company’s stock after acquiring an additional 11,547 shares during the period. Ritholtz Wealth Management’s holdings in Johnson & Johnson were worth $15,646,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $27,000. Clayton Financial Group LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $28,000. Semmax Financial Advisors Inc. raised its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC purchased a new position in Johnson & Johnson during the second quarter worth $35,000. Finally, Signature Resources Capital Management LLC lifted its position in shares of Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after acquiring an additional 184 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Bank of America increased their target price on Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. HSBC restated a “buy” rating and set a $240.00 price target on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Finally, Raymond James Financial raised their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $213.33.

Johnson & Johnson Stock Performance

JNJ opened at $218.81 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $220.11. The business’s 50 day moving average is $205.82 and its 200-day moving average is $187.17. The stock has a market cap of $527.18 billion, a PE ratio of 21.12, a price-to-earnings-growth ratio of 2.25 and a beta of 0.34.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.